Inve India ▾

Dr. Lal Path Labs share price & results

Dr. Lal Path Labs Ltd.· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Diagnostics chain: clinical labs, patient centres and pick-up points across India, Nepal and Bangladesh.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue798 ₹ crore+19.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin31.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit170 ₹ crore+26.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity23.95 %−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin16.79 %−4.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.31 %+1.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 of 9 judged targets kept · 9 open · verdicts reflect calls analysed to Q1 FY27.

Dr. Lal Path Labs Ltd. management guidance track record on Inve: 18 targets tracked across analysed earnings calls (7 achieved, 2 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue GrowthEarly to mid-teens
Call transcript, Q4 FY26 · 6 May 2026		Q4 FY26Q1 FY27:Revenue grew 19.1% YoY. Management now indicates a bias towards mid-teens growth for FY27, stating 'chances are we might be more towards mid-teens rather than early teens'.
Call transcript, Q1 FY27 · 30 Jul 2026		Revised Up
Patient Volume Growth7-8% (aspirational)
Call transcript, Q3 FY25 · 30 Jan 2025		Q3 FY25Q4 FY26:Sample volume growth of 12.9% in Q4 and 10.4% for FY26.
Call transcript, Q4 FY26 · 6 May 2026		Achieved
New Lab Additions15-20 for FY26
Call transcript, Q4 FY25 · 25 Apr 2025		Q4 FY25Q4 FY26:Added 14 new labs in FY26.
Call transcript, Q4 FY26 · 6 May 2026		Missed

Source: Inve Guidance Tracker for Dr. Lal Path Labs Ltd. · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Dr. Lal Path Labs Ltd.'s 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,855.6 +0.95% · +₹17.4

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −39.1% 1Y

₹1.5k₹2.0k₹2.5k₹3.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 31 Oct 2025Q3 FY26 — 30 Jan 2026Q4 FY26 — 6 May 2026Q1 FY27 — 30 Jul 2026

1Y: ₹3,048.2 on 24 Oct 2025 → ₹1,855.6. High ₹3,254.9 (3 Nov 2025), low ₹1,307.6 (23 Mar 2026).

Previous close
₹1,838.2
Market cap
₹32.0k Cr
52-week range
₹1,307.6 – ₹3,254.9
One year
−40.98%
Price to earnings (TTM to Jun 2026)
56.99×
Return on equity (TTM to Jun 2026)
23.95%

Overview

Symbol
NSE:LALPATHLAB
Exchange
NSE
Currency
INR

What Dr. Lal Path Labs Ltd. does

Based on the company's own presentations, annual report and earnings calls.

Dr. Lal PathLabs runs a pan-India pathology and radiology diagnostics network built around a hub-and-spoke model: a National Reference Lab in Delhi and Regional Reference Labs in Kolkata, Bengaluru and Mumbai anchor a chain of clinical laboratories, patient service centres (PSCs) and pick-up points (PUPs) that collect and process samples for walk-in, home-collection and B2B (hospital, doctor, corporate) customers. It earns by charging for pathology and radiology test panels sold both individually and as bundled preventive-health packages, and has extended the same model internationally with laboratories in Nepal and Bangladesh. Beyond routine testing, it runs specialised verticals in genomics, oncology, reproductive and auto-immune diagnostics under dedicated centres of excellence, and a newer preventive-wellness screening business.

Segments

  • Domestic Diagnostics (India)
  • International Diagnostics
Patient Service Centers (PSCs)
7,727
Pick-up Points (PUPs)
13,935
Clinical Laboratories
312
NABL-accredited Laboratories
53
CAP-accredited Laboratories
2
Reference Laboratories
National Reference Lab in Delhi plus Regional Reference Labs in Kolkata, Bengaluru and Mumbai
Founded 1949Headquarters New Delhi, India

How the price took the results

close before → close after

Q1 FY27
−0.2%
30 Jul
Q4 FY26
+3.2%
6 May
Q3 FY26
+1.0%
30 Jan
Q2 FY26
+1.5%
31 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Dr. Lal Path Labs Ltd.

Free account: one company. Everything above stays public.

Write why you follow Dr. Lal Path Labs Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Dr. Lal Path Labs Ltd.

Guides on how to read this kind of business and the numbers that matter.